Navigation Links
For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
Date:5/18/2009

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the TNF-alpha inhibitors, in particular, and constrain the biologics market," said Decision Resources Analyst Joanna Kim, M.Ed. "The potential of this oral Jak-3 inhibitor was demonstrated by its impressive efficacy in a recent Phase II clinical study for rheumatoid arthritis."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes
2. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
3. Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
4. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
5. An Aid to Tailoring Prostate Cancer Treatment
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
8. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
9. Can New Surgery Revolutionize Diabetes Treatment?
10. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
11. New Cancer Treatment Achieves First Mesothelioma Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Come to ... Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , ... our staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Reflections of God’s Work”: an enlightening ... God’s Work” is the creation of published author, Jerri Broglin, a survivor of great ... “I believe this a great eye-opener for those searching for answers, as we are ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to present ... be held at 7:30 pm on May 10th at the University Auditorium. , This ... Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick off ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is a place ... rendered in my Art and Music. These are created as Metaphysical Transformations where music, ... of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , Karen will ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... U.S. consumers can save an average of 70% when buying medication online from ... 97%) are available when purchasing from other countries. The report (chart below) compares ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology: